Form 4: OmniAb CEO Foehr Reports Equity Transactions

OmniAb, Inc.'s President and CEO, Matthew W. Foehr, reported the vesting of restricted stock units, a sell-to-cover transaction for taxes, and new grants of restricted stock units and stock options.

Summary

• Matthew W. Foehr, President and CEO of OmniAb, Inc., reported equity transactions on February 18, 2026.
• 58,333 shares of common stock were acquired due to the vesting of Restricted Stock Units (RSUs).
• 30,843 shares of common stock were sold at a weighted average price of $1.71 per share to cover tax withholding obligations related to RSU vesting.
• A new grant of 156,250 Restricted Stock Units (RSUs) was received.
• A new grant of 1,562,500 stock options was received with an exercise price of $1.71 per share.
• Following these transactions, Foehr directly beneficially owns 4,403,277 shares of common stock, 345,835 Restricted Stock Units, and 1,562,500 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it reflects ongoing executive compensation and alignment with long-term company performance, despite the routine tax-related share sale.

Positives

• The CEO received a significant new grant of 1,562,500 stock options, indicating continued long-term incentive alignment with company performance.
• A new grant of 156,250 Restricted Stock Units further aligns the CEO's interests with long-term shareholder value creation.

Negatives

• A portion of vested shares (30,843) was sold to cover tax obligations, which, while non-discretionary, reduces direct share ownership.
• The sale price for the tax-related disposition was $1.71 per share.

Future Outlook

The grants of Restricted Stock Units and stock options with future vesting schedules, commencing in 2026 and 2027, establish a long-term incentive structure for the CEO, aligning future performance with compensation and shareholder value creation.

Industry Context

StockSavvy.ai notes that equity compensation, including RSUs and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract and retain executive talent. This approach aligns management's long-term interests with shareholder value, and the reported vesting schedules are typical for incentivizing sustained performance and strategic execution.

Comparison to Industry Standards

• Equity compensation packages for CEOs in the biotech sector commonly feature a blend of RSUs and stock options, consistent with this filing.
• Executives at comparable early-stage biotech firms frequently receive substantial option grants with multi-year vesting schedules, designed to incentivize the achievement of drug development milestones and growth in market capitalization.
• The exercise price of $1.71 for the stock options matching the market price at the time of grant is a standard practice for incentive options.

Related Party Transactions

• Grant of 156,250 Restricted Stock Units to Matthew W. Foehr, President and CEO.
• Grant of 1,562,500 Stock Options to Matthew W. Foehr, President and CEO, with an exercise price of $1.71.
• Vesting of 58,333 Restricted Stock Units for Matthew W. Foehr, President and CEO.
• Sale of 30,843 shares by Matthew W. Foehr to cover tax withholding obligations related to RSU vesting.

Stakeholder Impact

• Shareholders: The CEO's increased equity holdings through new grants align his interests with shareholder value creation over the long term. The sell-to-cover transaction is a routine event with minimal impact on overall share structure.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Future vesting of the 156,250 RSU grant in three substantially equal annual installments beginning on February 18, 2027.
• Future vesting and exercisability of the 1,562,500 stock option grant, with 12.5% vesting 6 months after the grant date and the remainder in 42 substantially equal monthly installments thereafter.

Key Dates

Recommendation

This Form 4 primarily details routine executive compensation activities, including RSU vesting, a tax-related share sale, and new equity grants. While the new grants align the CEO's interests with long-term performance, these are standard compensation events and do not provide new fundamental information to warrant a change in investment recommendation. The filing does not contain information that would significantly alter the investment thesis for OmniAb, Inc.

Keywords

OmniAb, OABI, Matthew W. Foehr, SEC Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Compensation, CEO, Director